Pharmaceutical giant Sanofi plans to augment its corporate venture arm, Sanofi Ventures, with a $625 million capital infusion, increasing assets under management to over $1.4 billion. The evergreen fund will emphasize support for early-stage biotech startups, with strategic focus areas including immunology, rare diseases, neurology, vaccines, digital health, and AI-driven drug discovery platforms. This long-term investment strategy aims to provide stable backing through multiple financing rounds despite recent corporate setbacks, including disappointing late-stage trial outcomes for the eczema drug amlitelimab.